{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:13Z","timestamp":1793998033990,"version":"4.8.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"DOI":"10.1186\/s12917-026-05684-5","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:15:52Z","timestamp":1783430152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Off-label use of dapagliflozin in a dog with recurrent calcium oxalate urolithiasis: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Jay","family":"Pakhawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"12","key":"5684_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41585-020-00387-4","volume":"17","author":"A Alford","year":"2020","unstructured":"Alford A, Furrow E, Borofsky M, Lulich J. Animal models of naturally occurring stone disease. Nat Rev Urol. 2020;17(12):691\u2013705.","journal-title":"Nat Rev Urol"},{"issue":"10","key":"5684_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.2460\/javma.246.10.1098","volume":"246","author":"HS Allen","year":"2015","unstructured":"Allen HS, Swecker WS, Becvarova I, Weeth LP, Werre SR. Associations of diet and breed with recurrence of calcium oxalate cystic calculi in dogs. J Am Vet Med Assoc. 2015;246(10):1098\u2013103.","journal-title":"J Am Vet Med Assoc"},{"key":"5684_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s44324-025-00068-z","volume":"3","author":"P McLean","year":"2025","unstructured":"McLean P, Bennett J, Trey Woods E, et al. SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach. npj Metab Health Dis. 2025;3:29.","journal-title":"npj Metab Health Dis"},{"key":"5684_CR4","doi-asserted-by":"publisher","first-page":"150912","DOI":"10.1016\/j.bbrc.2024.150912","volume":"737","author":"Y Duan","year":"2024","unstructured":"Duan Y, Wang Q, Chen X, Deng G, Huang K, Sun F, Zhu J, Jiang K. Empagliflozin reduces renal calcium oxalate deposition in hyperoxaluria rats induced with ethylene glycol-ammonium chloride. Biochem Biophys Res Commun. 2024;737:150912.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"5684_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41591-024-03330-x","volume":"31","author":"MA Anderegg","year":"2025","unstructured":"Anderegg MA, Schietzel S, Bargagli M, Bally L, Faller N, Moor MB, Cereghetti GM, Roumet M, Trelle S, Fuster DG. Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial. Nat Med. 2025;31(1):286\u201393.","journal-title":"Nat Med"},{"key":"5684_CR6","doi-asserted-by":"publisher","first-page":"973129","DOI":"10.3389\/fcvm.2022.973129","volume":"9","author":"X Rong","year":"2022","unstructured":"Rong X, Zhu Y, Wen B, Liu K, Li X, Gou Q, Chen X. Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: a meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022;9:973129.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"5684_CR7","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1017\/S1368980022001033","volume":"25","author":"JS Wang","year":"2022","unstructured":"Wang JS, Chiang HY, Chen HL, Flores M, Navas-Acien A, Kuo CC. Association of water intake and hydration status with risk of kidney stone formation based on NHANES 2009\u20132012 cycles. Public Health Nutr. 2022;25(9):2403\u201314.","journal-title":"Public Health Nutr"},{"issue":"5","key":"5684_CR8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/jvim.14559","volume":"30","author":"JP Lulich","year":"2016","unstructured":"Lulich JP, Berent AC, Adams LG, Westropp JL, Bartges JW, Osborne CA. ACVIM small animal consensus recommendations on the treatment and prevention of uroliths in dogs and cats. J Vet Intern Med. 2016;30(5):1564\u201374.","journal-title":"J Vet Intern Med"},{"issue":"10","key":"5684_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2460\/javma.2001.218.1583","volume":"218","author":"JP Lulich","year":"2001","unstructured":"Lulich JP, Osborne CA, Lekcharoensuk C, Kirk CA, Allen TA. Effects of hydrochlorothiazide and diet in dogs with calcium oxalate urolithiasis. J Am Vet Med Assoc. 2001;218(10):1583\u20136.","journal-title":"J Am Vet Med Assoc"},{"key":"5684_CR10","unstructured":"Stevenson AE, Blackburn JM, Markwell PJ, Robertson WG. Nutrient intake and urine composition in calcium oxalate stone-forming dogs: comparison with healthy dogs and impact of dietary modification. Vet Ther. 2004 Fall;5(3):218\u2009\u2013\u200931."},{"key":"5684_CR11","doi-asserted-by":"publisher","first-page":"106524","DOI":"10.1016\/j.phrs.2022.106524","volume":"186","author":"G Anan","year":"2022","unstructured":"Anan G, Hirose T, Kikuchi D, Takahashi C, Endo A, Ito H, Sato S, Nakayama S, Hashimoto H, Ishiyama K, Kimura T, Takahashi K, Sato M, Mori T. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res. 2022;186:106524.","journal-title":"Pharmacol Res"},{"issue":"7","key":"5684_CR12","doi-asserted-by":"publisher","first-page":"e3003","DOI":"10.1210\/clinem\/dgac154","volume":"107","author":"P Balasubramanian","year":"2022","unstructured":"Balasubramanian P, Wanner C, Ferreira JP, Ofstad AP, Elsaesser A, Zinman B, Inzucchi SE. Empagliflozin and decreased risk of nephrolithiasis: a potential new role for SGLT2 inhibition? J Clin Endocrinol Metab. 2022;107(7):e3003\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"5684_CR13","doi-asserted-by":"publisher","first-page":"e14360","DOI":"10.14814\/phy2.14360","volume":"8","author":"T Masuda","year":"2020","unstructured":"Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8(2):e14360.","journal-title":"Physiol Rep"},{"issue":"5","key":"5684_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/MNH.0000000000000632","volume":"29","author":"JA Dominguez Rieg","year":"2020","unstructured":"Dominguez Rieg JA, Xue J, Rieg T. Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences. Curr Opin Nephrol Hypertens. 2020;29(5):523\u201330.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"5684_CR15","doi-asserted-by":"publisher","first-page":"115625","DOI":"10.1016\/j.bone.2020.115625","volume":"141","author":"KM Thrailkill","year":"2020","unstructured":"Thrailkill KM, Bunn RC, Uppuganti S, Ray P, Popescu I, Kalaitzoglou E, Fowlkes JL, Nyman JS. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits. Bone. 2020;141:115625.","journal-title":"Bone"},{"issue":"11","key":"5684_CR16","doi-asserted-by":"publisher","first-page":"e10242","DOI":"10.1002\/jbm4.10242","volume":"3","author":"G Cianciolo","year":"2019","unstructured":"Cianciolo G, De Pascalis A, Capelli I, Gasperoni L, Di Lullo L, Bellasi A, La Manna G. Mineral and Electrolyte Disorders With SGLT2i Therapy. JBMR Plus. 2019;3(11):e10242.","journal-title":"JBMR Plus"},{"issue":"10","key":"5684_CR17","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","volume":"38","author":"T Heise","year":"2016","unstructured":"Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 2016;38(10):2248\u201364. e5.","journal-title":"Clin Ther"},{"issue":"3","key":"5684_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/vcp.13225","volume":"52","author":"AK Selin","year":"2023","unstructured":"Selin AK, Lillieh\u00f6\u00f6k I, Forkman J, Larsson A, Pelander L, Strage EM. Biological variation of biochemical urine and serum analytes in healthy dogs. Vet Clin Pathol. 2023;52(3):461\u201374.","journal-title":"Vet Clin Pathol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-026-05684-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-026-05684-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-026-05684-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:16:30Z","timestamp":1791159390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12917-026-05684-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5684"],"URL":"https:\/\/doi.org\/10.1186\/s12917-026-05684-5","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Owner informed consent for all diagnostic and therapeutic interventions, as well as for inclusion of anonymized clinical data in this case report, was obtained at the time of treatment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"574"}}